| pubmed-article:2265862 | pubmed:abstractText | Adequate IgG-replacement therapy as treatment of choice for patients with humoral immunodeficiencies has revolutionized the outcome of these disorders. The action of intravenous immunoglobulins (IVIG) in autoimmune diseases, especially in idiopathic thrombocytic purpura seems to be due to Fc-receptor blockade and immunomodifying qualities. Thus far, treatment for patients with subclass deficiencies is restricted to persons with recurrent infections. | lld:pubmed |
